Papers › Accelerated Medicines Development using a Digital Formulator and a Self-Driving...
Accelerated Medicines Development using a Digital Formulator and a Self-Driving Tableting DataFactory
Faisal Abbas, Mohammad Salehian, Peter Hou, Jonathan Moores, Jonathan Goldie, Alexandros Tsioutsios, Victor Portela, Quentin Boulay, Roland Thiolliere, Ashley Stark, Jean-Jacques Schwartz, Jerome Guerin, Andrew G. P. Maloney, Alexandru A. Moldovan, Gavin K. Reynolds, Jérôme Mantanus, Catriona Clark, Paul Chapman, Alastair Florence, Daniel Markl
The archive published only this paper's code-link row. Authors, date and abstract are from arXiv's metadata (CC0), read from the Kaggle arXiv metadata snapshot of 2026-09-12 where its title matched the archive's; the title is the archive's.
Pharmaceutical tablet formulation and process development, traditionally a complex and multi-dimensional decision-making process, necessitates extensive experimentation and resources, often resulting in suboptimal solutions. This study presents an integrated platform for tablet formulation and manufacturing, built around a Digital Formulator and a Self-Driving Tableting DataFactory. By combining predictive modelling, optimisation algorithms, and automation, this system offers a material-to-product approach to predict and optimise critical quality attributes for different formulations, linking raw material attributes to key blend and tablet properties, such as flowability, porosity, and tensile strength. The platform leverages the Digital Formulator, an in-silico optimisation framework that employs a hybrid system of models - melding data-driven and mechanistic models - to identify optimal formulation settings for manufacturability. Optimised formulations then proceed through the self-driving Tableting DataFactory, which includes automated powder dosing, tablet compression and performance testing, followed by iterative refinement of process parameters through Bayesian optimisation methods. This approach accelerates the timeline from material characterisation to development of an in-specification tablet within 6 hours, utilising less than 5 grams of API, and manufacturing small batch sizes of up to 1,440 tablets with augmented and mixed reality enabled real-time quality control within 24 hours. Validation across multiple APIs and drug loadings underscores the platform's capacity to reliably meet target quality attributes, positioning it as a transformative solution for accelerated and resource-efficient pharmaceutical development.
Code
Repository list and official/mentioned flags are the archive's, frozen 2025-07-28. Reachability, where shown, is from one Syntology probe window (2026-09-16 to 2026-09-18); repositories not probed show nothing. GitHub stars are not tracked.
Code Syntology ran Syntology
Not run by Syntology. Nothing on this page verifies that the listed code works.
Results from the paper archive 2025-07-28
No leaderboard rows for this paper in the archive.
Report a problem or propose a change · a person checks every report against the paper or source before anything changes; decisions are listed on /corrections